Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Mahlangu, Johnny, Oldenburg, Johannes, Paz-Priel, Ido, Negrier, Claude, Niggli, Markus, Mancuso, M. Elisa, Schmitt, Christophe, Jiménez-Yuste, Victor, Kempton, Christine, Dhalluin, Christophe, Callaghan, Michael U, Bujan, Willem, Shima, Midori, Adamkewicz, Joanne I, Asikanius, Elina, Levy, Gallia G, Kruse-Jarres, Rebecca
Published in The New England journal of medicine (30.08.2018)
Published in The New England journal of medicine (30.08.2018)
Get full text
Journal Article
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
Callaghan, Michael U., Negrier, Claude, Paz-Priel, Ido, Chang, Tiffany, Chebon, Sammy, Lehle, Michaela, Mahlangu, Johnny, Young, Guy, Kruse-Jarres, Rebecca, Mancuso, Maria Elisa, Niggli, Markus, Howard, Monet, Bienz, Nives Selak, Shima, Midori, Jiménez-Yuste, Victor, Schmitt, Christophe, Asikanius, Elina, Levy, Gallia G., Pipe, Steven W., Oldenburg, Johannes
Published in Blood (22.04.2021)
Published in Blood (22.04.2021)
Get full text
Journal Article
Low immunogenicity of emicizumab in persons with haemophilia A
Schmitt, Christophe, Emrich, Thomas, Chebon, Sammy, Fernandez, Elena, Petry, Claire, Yoneyama, Koichiro, Kiialainen, Anna, Howard, Monet, Niggli, Markus, Paz‐Priel, Ido, Chang, Tiffany
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.11.2021)
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.11.2021)
Get full text
Journal Article
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
Pipe, Steven W., Collins, Peter, Dhalluin, Christophe, Kenet, Gili, Schmitt, Christophe, Buri, Muriel, Jiménez-Yuste, Víctor, Peyvandi, Flora, Young, Guy, Oldenburg, Johannes, Mancuso, Maria Elisa, Kavakli, Kaan, Kiialainen, Anna, Deb, Sonia, Niggli, Markus, Chang, Tiffany, Lehle, Michaela, Fijnvandraat, Karin
Published in Blood (04.04.2024)
Published in Blood (04.04.2024)
Get full text
Journal Article
Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study
Pipe, Steven, Collins, Peter, Dhalluin, Christophe, Kenet, Gili, Schmitt, Christophe, Buri, Muriel, Jiménez-Yuste, Víctor, Peyvandi, Flora, Young, Guy, Oldenburg, Johannes, Mancuso, Maria Elisa, Kavakli, Kaan, Kiialainen, Anna, Chang, Tiffany, Lehle, Michaela, Niggli, Markus, Fijnvandraat, Karin
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
Kiialainen, Anna, Niggli, Markus, Kempton, Christine L., Castaman, Giancarlo, Chang, Tiffany, Paz‐Priel, Ido, Adamkewicz, Joanne I., Levy, Gallia G.
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.11.2022)
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.11.2022)
Get full text
Journal Article
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial
Reyes, Adriana, Révil, Cédric, Niggli, Markus, Chebon, Sammy, Schlagmüller, Simone, Flacke, Jan-Paul, Zortel, Max, Paz-Priel, Ido, Asikanius, Elina, Hampton, Roger, Mahajan, Anadi, Schmidt, Elvira, Edwards, Susan C.
Published in Current medical research and opinion (02.12.2019)
Published in Current medical research and opinion (02.12.2019)
Get full text
Journal Article
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
Schmitt, Christophe, Mancuso, Maria Elisa, Chang, Tiffany, Podolak‐Dawidziak, Maria, Petry, Claire, Sidonio Jr, Robert, Yoneyama, Koichiro, Key, Nigel S., Niggli, Markus, Lehle, Michaela, Peyvandi, Flora, Oldenburg, Johannes
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.01.2023)
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.01.2023)
Get full text
Journal Article
Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3
Kiialainen, Anna, Niggli, Markus, Kempton, Christine L., Castaman, Giancarlo, Chang, Tiffany Y., Paz-Priel, Ido, Adamkewicz, Joanne I, Levy, Gallia G.
Published in Blood (13.11.2019)
Published in Blood (13.11.2019)
Get full text
Journal Article
Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience
Callaghan, Michael, Trzaskoma, Benjamin, Ko, Richard H., Lee, Lucy, Patel, Anisha M., Tzeng, Eunice, Shah, Michelle Lynn, Chang, Tiffany Y., Niggli, Markus, Dhalluin, Christophe, Mahlangu, Johnny
Published in Blood (13.11.2019)
Published in Blood (13.11.2019)
Get full text
Journal Article
The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
Skinner, Mark W., Négrier, Claude, Paz‐Priel, Ido, Chebon, Sammy, Jiménez‐Yuste, Victor, Callaghan, Michael U., Lehle, Michaela, Niggli, Markus, Mahlangu, Johnny, Shapiro, Amy, Shima, Midori, Campinha‐Bacote, Avrita, Levy, Gallia G., Oldenburg, Johannes, Mackensen, Sylvia, Pipe, Steven W.
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.09.2021)
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.09.2021)
Get full text
Journal Article
Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials
Bogman, Katrijn, Brumm, Jochen, Hofmann, Carsten, Giraudon, Mylène, Niggli, Markus, Sturm-Pellanda, Carolina, Sauter, Annette, Sturm, Stefan, Mangold, Bernhard, Schmitt, Christophe
Published in Clinical pharmacokinetics (01.09.2019)
Published in Clinical pharmacokinetics (01.09.2019)
Get full text
Journal Article
Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide
Giraudon, Mylène, Sturm, Stefan, Lambert, Nathalie, Niggli, Markus, Brumm, Jochen, Mangold, Bernhard, Schmitt, Christophe
Published in Diabetes, obesity & metabolism (01.04.2017)
Published in Diabetes, obesity & metabolism (01.04.2017)
Get full text
Journal Article
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
Kempton, Christine, Trask, Peter, Parnes, Aric, Niggli, Markus, Campinha‐Bacote, Avrita, Callaghan, Michael, O'Connell, Niamh, Paz‐Priel, Ido, Mahlangu, Johnny N.
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.03.2021)
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.03.2021)
Get full text
Journal Article
Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)
Callaghan, Michael U., Négrier, Claude, Paz-Priel, Ido, Chang, Tiffany, Chebon, Sammy, Lehle, Michaela, Mahlangu, Johnny, Young, Guy, Kruse-Jarres, Rebecca, Mancuso, Maria Elisa, Niggli, Markus, Kuebler, Peter, Selak Bienz, Nives, Shima, Midori, Jimenez-Yuste, Victor, Schmitt, Christophe, Asikanius, Elina, Levy, Gallia, Pipe, Steven W., Oldenburg, Johannes
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087
Reyes, Adriana, Révil, Cédric, Niggli, Markus, Chebon, Sammy, Schlagmüller, Simone, Flacke, Jan-Paul, Zortel, Max, Paz-Priel, Ido, Asikanius, Elina, Hampton, Roger, Mahajan, Anadi, Schmidt, Elvira, Edwards, Susan C
Published in Current medical research and opinion (02.07.2020)
Published in Current medical research and opinion (02.07.2020)
Get more information
Journal Article
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
Kruse-Jarres, Rebecca, Peyvandi, Flora, Oldenburg, Johannes, Chang, Tiffany, Chebon, Sammy, Doral, Michelle Y., Croteau, Stacy E., Lambert, Thierry, Kempton, Christine L., Pipe, Steven W., Ko, Richard H., Trzaskoma, Benjamin, Dhalluin, Christophe, Bienz, Nives Selak, Niggli, Markus, Lehle, Michaela, Paz-Priel, Ido, Young, Guy, Jiménez-Yuste, Víctor
Published in Blood advances (27.12.2022)
Published in Blood advances (27.12.2022)
Get full text
Journal Article
Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies
Jimenez-Yuste, Victor, Shima, Midori, Paz-Priel, Ido, Parnes, Aric, Lehle, Michaela, Giermasz, Adam, Campinha-Bacote, Avrita, Niggli, Markus, Windyga, Jerzy, Chebon, Sammy, Trask, Peter, Mahlangu, Johnny, Pipe, Steven, Oldenburg, Johannes
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article
Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
Mahlangu, Johnny, Jiménez-Yuste, Víctor, Ventriglia, Giuliana, Niggli, Markus, Barlera, Simona, Hermans, Cédric, Lehle, Michaela, Chowdary, Pratima, Jew, Lyle, Windyga, Jerzy, Frenzel, Laurent, Schmitt, Christophe, Castaman, Giancarlo, Pipe, Steven W.
Published in Research and practice in thrombosis and haemostasis (01.02.2024)
Published in Research and practice in thrombosis and haemostasis (01.02.2024)
Get full text
Journal Article
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks
Kiialainen, Anna, Adamkewicz, Joanne I., Petry, Claire, Oldenburg, Johannes, Pipe, Steven W., Young, Guy, Mahlangu, Johnny, Lehle, Michaela, Niggli, Markus, Castaman, Giancarlo, Jiménez-Yuste, Víctor, Shima, Midori, Négrier, Claude, Schmitt, Christophe
Published in Research and practice in thrombosis and haemostasis (01.01.2024)
Published in Research and practice in thrombosis and haemostasis (01.01.2024)
Get full text
Journal Article